

M.Ch. – GYNAECOLOGICAL ONCOLOGY

**Paper I – BASIC SCIENCES AND RECENT ADVANCES IN
GYNAECOLOGIC ONCOLOGY**

Q.P. Code: 181961

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on:

(2 x 15 = 30)

1. 22 year old unmarried girl has undergone treatment for Hormone receptor positive Breast Cancer. She is advised adjuvant chemotherapy and Radiotherapy. What are her risks of fertility loss? Explain different options of fertility preservation for her.
2. Explain in detail about Cervical cancer Carcinogenesis. Explain in detail the management options available for stage Ib3 and IIA2 carcinoma cervix and justify with evidence.

II. Write notes on:

(10 x 7 = 70)

1. Apoptosis.
2. Linear energy transfer.
3. Phase III trials.
4. Sentinel node biopsy in carcinoma endometrium.
5. Peritoneal cancer index.
6. Recent concepts in ovarian carcinogenesis.
7. Current role of minimally invasive surgery in carcinoma cervix.
8. ESMO-ESGO criteria for assignment of primary site in Extrauterine serous carcinoma.
9. PORTEC III trial.
10. Odds ratio.

M.Ch. – GYNAECOLOGICAL ONCOLOGY

**Paper I – BASIC SCIENCES AND RECENT ADVANCES IN
GYNAECOLOGIC ONCOLOGY**

Q.P. Code: 181961

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on:

(2 x 15 = 30)

1. Discuss the genetic basis of tumorigenesis and the roles of oncogenes and tumour suppressor genes.
2. Discuss the recent advances in immunotherapy of gynaecologic cancers.

II. Write notes on:

(10 x 7 = 70)

1. Cancer stem cells.
2. Cyclin dependent kinases.
3. Angiogenesis.
4. Tumour markers in non-epithelial ovarian cancers.
5. Magnetic Resonance Imaging.
6. Laparoscopy in early stage ovarian cancer.
7. Brachytherapy principles.
8. PIPAC.
9. Sentinel lymph node mapping.
10. Bacteraemia.

(MCH 0821)

AUGUST 2021

Sub. Code: 1961

M.Ch. – GYNAECOLOGICAL ONCOLOGY

**Paper I – BASIC SCIENCES AND RECENT ADVANCES IN
GYNAECOLOGIC ONCOLOGY**

Q.P. Code: 181961

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on:

(2 x 15 = 30)

1. Discuss tumour angiogenesis and the role of antiangiogenic agents in ovarian cancer.
2. Discuss the role of fertility preservation in gynaec cancer patients.

II. Write notes on:

(10 x 7 = 70)

1. Genetic counselling.
2. Role of PETCT in gynaecological cancer.
3. Classification of uterine sarcomas and management of leiomyosarcoma.
4. Cell cycle.
5. Management of recurrent GTN.
6. Primary HPV testing for cervical cancer prevention.
7. Check point inhibitors in gynaecological cancers.
8. Role of HIPEC in ovarian cancer.
9. Implications of the GROINSS trial.
10. Minimal access surgery for cervical cancer.

THE TAMIL NADU DR.M.G.R. MEDICAL UNIVERSITY

(MCH 0822)

AUGUST 2022

Sub. Code: 1961

M.Ch. – GYNAECOLOGICAL ONCOLOGY

**Paper I – BASIC SCIENCES AND RECENT ADVANCES IN
GYNAECOLOGIC ONCOLOGY**

Q.P. Code: 181961

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on:

(2 x 15 = 30)

1. Describe the branches of the abdominal aorta and retroperitoneal lymph node distribution. Discuss the evidence for lymphadenectomy in ovarian cancer.
2. Elaborate on the WHO 2020 classification of cervical cancer pathology. Discuss the role of IHC and HPV in the diagnosis of cervical cancer. Outline the management of adenocarcinomas of the cervix.

II. Write notes on:

(10 x 7 = 70)

1. Recent concepts in ovarian carcinogenesis.
2. Gene repair mechanisms.
3. Evaluation of a 60 year post-menopausal lady with adnexal mass.
4. Odds Ratio.
5. Role of imaging Carcinoma Vulva.
6. CA125.
7. Lynch syndrome.
8. Discuss the role of OCP in cancer preventions.
9. Tumour infiltrating lymphocytes.
10. Obesity – its role in oncogenesis.

THE TAMIL NADU DR.M.G.R. MEDICAL UNIVERSITY

(MCH 0124)

JANUARY 2024

Sub. Code: 1961

M.Ch. – GYNAECOLOGICAL ONCOLOGY

**PAPER I – BASIC SCIENCES AND RECENT ADVANCES IN
GYNAECOLOGIC ONCOLOGY**

Q.P. Code: 181961

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on:

(2 x 15 = 30)

1. Discuss Lynch Syndrome and its screening and prevention.
2. Discuss molecular alterations involved in cancer pathogenesis.

II. Write notes on:

(10 x 7 = 70)

1. DNA repair mechanisms.
2. Peritoneal cancer index.
3. Sentinel node mapping in endometrial cancer.
4. PARP inhibitors.
5. ARIEL 3 study.
6. MRI in gynaecological cancers.
7. Robotic surgery in gynaecological cancers.
8. Pelvic exenteration.
9. Total parental nutrition.
10. PORTEC 4a trial.

THE TAMIL NADU DR.M.G.R. MEDICAL UNIVERSITY

(MCH 0225)

FEBRUARY 2025

Sub. Code: 1961

M.Ch. BRACH XII – GYNAECOLOGICAL ONCOLOGY

**PAPER I – BASIC SCIENCES & RECENT ADVANCES IN GYNAECOLOGIC
ONCOLOGY**

Q.P. Code: 181961

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on:

(2 x 15 = 30)

1. Discuss the role of imaging in adnexal masses with special reference to International Ovarian Tumour Analysis ADNEX model. How does it differ from the ORADS scoring system?
2. Discuss the lymphatic drainage of vulva with illustration. What is the evidence of lymphadenectomy in carcinoma vulva.

II. Write notes on:

(10 x 7 = 70)

1. Performance indices in patients with malignancy.
2. Methotrexate.
3. Homologous Repair Deficiency mutations.
4. BIAS in clinical trials.
5. WHO 2020 classification in pathology of cervical cancers.
6. Atypical fibroids.
7. Immune check point inhibitors in endometrial cancer.
8. Therapeutic cancer vaccine.
9. HPV induced carcinogenesis in cervical cancer.
10. Describe the anatomy of the abdominal aorta and the Inferior vena cava with illustrations.

THE TAMIL NADU Dr. M.G.R. MEDICAL UNIVERSITY

(MCH 0125)

JANUARY 2026

Sub. Code: 1961

M.Ch. – GYNAECOLOGICAL ONCOLOGY

**PAPER I – BASIC SCIENCES & RECENT ADVANCES IN
GYNAECOLOGIC ONCOLOGY**

Q.P. Code: 181961

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on:

(2 x 15 = 30)

1. Discuss the three lymphatic pathways of the uterus. Elaborate on the utilization an evidence with regards to sentinel node mapping in high risk endometrial cancer.
2. What is Circulating Cell-Free DNA? Discuss the role of Circulating Cell Free DNA in ovarian cancer.

II. Write notes on:

(10 x 7 = 70)

1. Risk factors for recurrence in cervical adenocarcinoma.
2. GROINSS-V II trial.
3. The role of imaging in cervical cancer staging.
4. Molecular subtyping of high grade serous ovarian cancer and its prognostic implication.
5. Avascular spaces in the pelvis developed during radical hysterectomy.
6. KELIM score in ovarian cancer.
7. Apixaban as thromboprophylaxis in gynaec cancer surgeries.
8. What is chemotherapy response score? Discuss its prognostic implications.
9. Role of immunohistochemistry in endometrial neoplasia.
10. Cross sectional study design.
